Charles River Laboratories International has had a string of noteworthy activities, most prominently the announcement of several strategic collaborations aimed at accelerating cutting-edge neuroscience research. Affiliations with CEBINA and Autobahn Labs constitute prominent partnerships designed to foster academic drug discovery. However, the company recently reported lower than expected forecasts for 2024, attributing it to reduced demand for drug development services. In a drastic turn of events, Charles River Laboratories plans on laying off around 650 employees. Despite this, certain investment firms like Thrivent Financial for Lutherans and Edgestream Partners L.P. have offloaded considerable shares of the company, while others like Kayne Anderson Rudnick Investment Management LLC and Envestnet Asset Management Inc. have chosen to acquire a substantial amount. Charles River Laboratories also recently acquired a lending collaboration with Gates Institute and is said to introduce an animal-free bacterial endotoxin test. On a cautionary note, allegations of securities fraud have been levelled against the company with formal investigations now underway.
Charles River Laboratories International CRL News Analytics from Wed, 31 May 2023 07:00:00 GMT to Sun, 22 Sep 2024 11:28:11 GMT -
Rating -4
- Innovation 7
- Information 6
- Rumor -6
